Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats  by Lewin, Ewa et al.
Kidney International, Vol. 64 (2003), pp. 63–70
Autoregulation in the parathyroid glands by PTH/PTHrP
receptor ligands in normal and uremic rats
EWA LEWIN, BARTOLOME GARFIA, YOLANDA ALMADEN, MARIANO RODRIGUEZ,
and KLAUS OLGAARD
Nephrological Department B, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark; Nephrological Department
P, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and Unidad de Investigacio´n, Hospital Universitario
Reina Sofia, Cordoba, Spain
were significantly increased. The CRF rats on high phosphorusAutoregulation in the parathyroid glands by PTH/PTHrP re-
diet had significant hypocalcemia (Ca, 1.04  0.02 mmol/Lceptor ligands in normal and uremic rats.
vs. 1.28 0.03 mmol/L, P 0.001), hyperphosphatemia (3.48Background. The secretion of parathyroid hormone (PTH)
0.3 mmol/L vs. 2.25  0.1 mmol/L, P  0.001) and severefrom the parathyroid glands might be regulated by autocrine/
secondary HPT, PTH (984  52 pg/mL vs. 226  32 pg/mL,paracrine factors. We have previously shown that N-terminal
P  0.001) compared to CRF rats on a standard phosphorusparathyroid hormone-related protein (PTHrP) enhanced the
diet. The maximal PTH response to hypocalcemia was en-secretory PTH response to low calcium in vivo and in vitro
hanced in CRF rats (maximum PTH 382  58 pg/mL vs. 196 in rat parathyroid glands. N-terminal PTHrP fragments are
29 pg/mL in normal rats, P  0.01) and further enhanced byequipotent to N-terminal PTH as ligands for the PTH/PTHrP
PTHrP 1-40 to 826  184 pg/mL (P  0.01). The secretoryreceptor that is demonstrated in parathyroid tissue. This sup-
ports the possibility that the parathyroid cells respond to PTH/ capacity of the parathyroid glands in response to low Ca
PTHrP receptor ligands and as such are target for an autoregu- was severely diminished in uremia. In CRF rats given a high
latory action of PTH and PTHrP. Our aim was to search for phosphorus diet, the basal PTH levels were at the upper part
the PTH/PTHrP receptor in rat parathyroid glands and to of the calcium/PTH curve, and the induction of more marked
examine the effects of PTHrP 1-40 on PTH secretion in in vivo hypocalcemia did not stimulate PTH secretion further (maxi-
models of secondary hyperparathyroidism (HPT) in uremic mum PTH 1475  208 pg/mL vs. basal 1097  69 pg/mL, NS).
rats. PTHrP, however, further enhanced the maximal PTH levels
Methods. PTH secretion was examined during ethylenegly- significantly (maximum PTH 3142  296 pg/mL, P  0.01).
col tetraacetic acid (EGTA)-induced hypocalcemia both with The presence of the PTH/PTHrP receptor in the rat parathy-
and without PTHrP. Five groups, each of six normal rats, re- roid glands was confirmed by RT-PCR technique.
ceived a bolus of increasing doses of 0.1, 1.0, 10, and 100 g Conclusion. PTHrP enhanced significantly, in a dose-related
of PTHrP 1-40, or vehicle only. Chronic renal failure (CRF) manner, the low Ca-stimulated PTH secretion in normal
was induced by 5/6 nephrectomy. One group of 12 CRF rats rats. The PTH/PTHrP receptor is present in rat parathyroid
received a standard diet, while another CRF group of 18 rats glands. The impaired secretory capacity of the parathyroid
received a high phosphorus diet to induce more severe HPT. glands in uremic rats is significantly enhanced by PTHrP. An
After 8 weeks of uremia, the rats were infused with EGTA autocrine/paracrine role in the parathyroid glands of the PTH/
and PTHrP 1-40 or vehicle. The presence of the PTH/PTHrP PTHrP receptor targeting peptides, PTHrP and PTH, is sug-
receptor in the rat parathyroid glands was examined by reverse gested. Thus, it is hypothesized that PTH during hypocalcemia
transcription-polymerase chain reaction (RT-PCR) technique. might have a positive auto-feedback regulatory role on its own
PTH was measured by a rat PTH assay that does not cross- secretion.
react with PTHrP.
Results. In a dose-related manner, PTHrP enhanced the
PTH response to hypocalcemia in normal rats. A similar rate
It has previously been shown by our group, that N-ter-of decrease of plasma Ca was induced by EGTA in all
experimental groups. In CRF rats, plasma creatinine (0.99  minal parathyroid hormone-related protein (PTHrP)
0.10 mmol/L vs. 0.33  0.01 mmol/L, P  0.001) and plasma 1-40 and 1-86, used as surrogate for parathyroid hormone
PTH (226  32 pg/mL vs. 69  16 pg/mL, P  0.001) levels (PTH), enhance the secretory response of PTH to hypo-
calcemia in rats in vivo [1]. This effect of PTHrP was
immediate, taking place within 5 minutes. No effect ofKey words: secondary hyperparathyroidism, calcium/PTH curve, auto-
crine-paracrine factor, PTHrP, PTH/PTHrP receptor, uremia. PTHrP was found in vivo during normo- and hypercalce-
mia. In that investigation, it was ensured that the periph-Received for publication October 18, 2002
eral metabolism of PTH was not affected by PTHrP andand in revised form December 16, 2002, and January 28, 2003
Accepted for publication February 24, 2003 that there was no cross-reactivity of PTHrP in the rat
PTH assay [1]. A direct effect of PTHrP on the rat 2003 by the International Society of Nephrology
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parathyroids was confirmed by the demonstration in METHODS
vitro that low Ca-induced PTH secretion was aug- Animals
mented by PTHrP [1].
Inbred male Dark Aguti (DA) rats (Moellegaarden,
These results support the possibility that the parathy-
Denmark) were used, weighing 200 to 225 g at the start
roid cells respond to PTH/PTHrP receptor ligands. PTH
of the study. The experimental studies on the rats were
and PTHrP might as equipotent ligands for the receptor
performed in accordance with the NIH Guidelines for
have regulatory functions on the secretion of PTH.
Care and Use of Laboratory Animals and was approved
The mature PTHrP protein contains a limited region of
by our institution. The experimental procedures were
sequence homology with PTH in its immediate N-terminal
performed in rats under anesthesia with 50 g/kg intra-
region. PTH and PTHrP activate a common G-protein
peritoneal injection of pentobarbital (Mebumal).coupled receptor, the PTH/PTHrP type 1 receptor [2–4]
and PTHrP was used as a surrogate for PTH because it Uremia
mimics the action of PTH by acting through the PTH/
Chronic renal failure (CRF) was induced by one-stepPTHrP receptor.
5/6 nephrectomy. A group of 12 CRF rats was given aPTHrP is expressed in a wide variety of normal fetal
standard diet containing 0.9% calcium, 0.7% phospho-and adult tissues [5–13]. The PTH/PTHrP receptor is
rus, and 1000 IU vitamin D/kg. To induce more severefrequently expressed in cells that produce PTHrP or in
HPT, another group of 18 CRF rats was given a highcells immediately adjacent to PTHrP-producing cells.
phosphorus diet containing 0,9% calcium, 1.5% phos-This spatial proximity, together with the fact that little,
phorus, and 1000 IU vitamin D/kg. The duration of ure-if any, PTHrP circulates under normal physiologic condi-
mia was 8 weeks. A group of 12 normal control rats wastions have led to the view that PTHrP is a locally acting
given a standard diet. Rats were allowed free access toautocrine/paracrine factor [3, 14]. PTHrP mRNA is ex-
food and water.pressed in normal human and bovine parathyroid tissues
[13, 15, 16]. The expression of PTHrP in the parathyroid Peptide
glands is not only a feature of neoplastic transformation,
PTHrP 1-40 was obtained from Saxon Biochemicals,although abnormal expression of PTHrP mRNA and
GMBH, Hannover, Germany. PTHrP was first dissolvedprotein has been found in human parathyroid adenomas,
in deionized water to a concentration of 1 mg/mL andhyperplasia, and carcinomas [13, 17–19], but it could be
then diluted in saline to the concentration needed.a feature of normal physiology, as well.
PTH and PTHrP have been demonstrated to be colo-
Induction of hypocalcemiacalized in the same secretory granules and to be secreted
Hypocalcemia was induced by infusion of 30 mmol/Lsimultaneously from parathyroid adenomas [19]. The
ethyleneglycol tetraacetic acid (EGTA), 3 mL/hourPTH/PTHrP receptor has been demonstrated in human
through a catheter inserted in the femoral vein. Samplesparathyroid tissue [18]. However, the physiologic role of
for determination of plasma PTH and plasma Ca werePTHrP in the parathyroid glands remains to be estab-
taken at 0, 5, 10, 20, 30, 40, and 50 minutes from alished [3].
corresponding catheter in the femoral artery. The sampleN-terminal PTHrP fragments are equipotent to N-termi-
volume of 0.8 mL was replaced by 0.8 mL of saline,nal PTH fragments as ligands for the PTH/PTHrP recep-
resulting in the same weight of the rats before and aftertor [20]. Therefore, in the present study, N-terminal
the experiments.PTHrP was used as a surrogate for N-terminal PTH due
Maximum PTH is the highest PTH value obtainedto the properties of the rat PTH assay, which comeasures
during induction of hypocalcemia.the N-terminal PTH fragments (i.e., rat, human, and
The relative secretory capacity is defined as the rela-bovine PTH), but not PTHrP. The uremic condition is
tive increase in PTH secretion from baseline in responseassociated with disturbances in calcium, phosphorus, and
to an acute induction of hypocalcemia, expressed in per-PTH metabolism leading to development of secondary
cent of the basal PTH level.hyperparathyroidism (HPT). The Ca/PTH relation-
ship is abnormal in uremia; the PTH secretion, at the
Experimental protocolsbasal condition, is toward the upper part of the Ca/
Dose-response study. At time 0, one of five groups,PTH curve, and the maximal secretory response to hypo-
each with six normal rats, received vehicle or an intrave-calcemia is often increased [21].
nously bolus dose of 0.1, 1.0, 10, or 100 g of PTHrPThe aim of present investigation therefore was to
1-40. Hypocalcemia was then induced by an infusion ofsearch for the PTH/PTHrP receptor in the parathyroid
30 mmol/L EGTA and samples for determination ofglands and to examine the effects of PTHrP 1-40 on PTH
plasma PTH and plasma Ca were taken as describedsecretion in in vivo models of secondary HPT in uremic
rats. above.
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The effect of PTHrP on low Ca-stimulated PTH secre- Plasma measurements
tion in vivo in uremic rats kept on standard diet. A group Plasma creatinine, urea, phosphorus, and total calcium
of uremic rats received a bolus of 1 mL of 100 g/mL were measured by an ETACHEM 250 Analyzer (Kodak,
of PTHrP 1-40 at time 0 (N  6). Another group of Rochester, NY, USA). Plasma PTH was measured by a
uremic rats received 1 mL of vehicle only (N 6). Hypo- rat PTH immunoradiometric assay (IRMA) from Immu-
calcemia was then induced and samples for determina- notopics, San Clemente, CA, USA. The intra-assay coef-
tion of plasma PTH and plasma Ca were taken as ficient of variance in our laboratory was 4% and in-
described above. terassay coefficient of variance 5%. PTHrP 1-40 did not
cross-react with the rat PTH assay. No cross-reactiv-The effect of PTHrP on low Ca-stimulated PTH
ity with C-terminal PTH fragments was found in oursecretion in vivo in uremic rats kept on a high phosphorus
laboratory [1, 22]. Plasma Ca at actual pH was mea-diet. A group of uremic hyperphosphatemic rats re-
sured by a calcium-selective electrode (Radiometer, Co-ceived a bolus of 1 mL of 100 g/mL of PTHrP 1-40 at
penhagen, DK).time 0 (N  9). Another group of uremic hyperphos-
phatemic rats received 1 mL of vehicle only (N  9).
StatisticsThen, hypocalcemia was induced and samples for deter-
The results are expressed as mean  SEM. Mann-mination of plasma PTH and plasma Ca were taken
Whitney test or t test were used for comparison betweenas described above.
groups. P  0.05 is considered significant.
Parathyroid PTH/PTHrP receptor—RNA isolation
and reverse transcription-polymerase chain RESULTS
reaction (RT-PCR)
In uremic rats, plasma creatinine and urea levels were
Two rat parathyroid glands and a small slice of kidney significantly increased (P  0.001), as shown in Table 1.
cortex (1 mm3) were obtained for total RNA extraction. The uremic rats kept on a high phosphorus diet devel-
Tissue samples were separately placed in nuclease-free oped significant hypocalcemia (P  0.001), hyperphos-
1.5 mL microcentrifuge tubes. Then, 400 L of a lysis/ phatemia (P  0.001), and severe secondary HPT (P 
binding buffer from a commercial kit for tissue total 0.001), as compared to normal rats and uremic rats given
RNA extraction (High Pure RNA Tissue Kit; Roche, a standard diet (Table 1).
Mannheim; Germany) were added to the samples. The The effect in vivo of increasing doses of PTHrP 1-40
tissues (parathyroid and kidney cortex) were ultrason- on the low calcium–induced PTH secretion in the rat is
shown in Figure 1A. This effect was clearly dose-relatedicated for 5 minutes at 4C to allow for complete cell
with increasing doses of PTHrP resulting in an enhancedrupture. Subsequently, tissues were homogenized by
PTH response to hypocalcemia (P  0.01). The ratespassing the lysate 10 to 20 times through a 20 gauge
of reduction of plasma Ca levels were not differentneedle attached to a sterile plastic syringe until a homo-
between the experimental groups (Fig. 1B).geneous lysate was achieved. Then, total RNA was ex-
In order to ensure the presence of the PTH/PTHrPtracted using the High Pure RNA Tissue Kit. Total RNA
receptor in the parathyroid glands, three sets of RT-was quantified by spectrophotometry. The PTH/PTHrP
PCR measurements were performed in parathyroidreceptor in parathyroid glands and kidney cortex were
glands, using normal kidney tissue as control. These in-amplified using the kit, Access RT-PCR System (Pro-
vestigations clearly demonstrated the presence of themega, Madison WI, USA) using a specific primer and
PTH/PTHrP receptor in the parathyroid glands as well100 ng of kidney cortex total RNA and 200 ng of parathy-
as in the kidneys, as shown in Figure 2.roid total RNA per sample. Kidney cortex and parathy-
The relative secretory capacity of the parathyroidroid PTH/PTHrP receptor-mRNA were amplified at 24
glands in normal rats, uremic rats kept on a standard
and 40 cycles, respectively. DNA amplifications were diet, and uremic rats kept on a high phosphorus diet is
processed by a Genetic Analyzer Abi Prism 310 (Perkin shown in Figure 3. The relative secretory capacity was
Elmer, Foster City, CA, USA). Data were analyzed using significantly decreased (P  0.05) in uremia and practi-
specific software Gene Scan version 3.1/1998 (Perkin cally zero in uremic rats kept on a high phosphorus diet.
Elmer). The PTH secretory response to PTHrP and hypocal-
The PTH/PTHrP receptor primers were: cemia in normal rats and in uremic rats kept on a stan-
dard diet is shown in Figure 4. In uremic rats, the PTH
PTH/PTHrP receptor sense 5-FAM-TAC levels induced by hypocalcemia were significantly en-
CGGAAGCTGCTCAAATCC hanced compared to that of normal rats and this response
PTH/PTHrP receptor antisense 5-GCGACA was further significantly enhanced by PTHrP (P  0.01).
In normal control rats, PTH increased from a basal PTHAAAAATCCCTGGAAG
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Table 1. Plasma parameters of normal and uremic rats
Creatinine Urea Ca Phosphorus Parathyroid
lmol/L mmol/L mmol/L mmol/L hormone pg/mL
Normal N  12 331 61 1.260.04 1.850.1 6916
Chronic renal failure standard diet N  12 9910a 269a 1.280.03a 2.250.1 22632a
Chronic renal failure high phosphorus diet N  18 865a 162a 1.040.02a,b 3.480.3a,b 98452a,b
a P  0.001 versus normal rats; b P  0.001 versus chronic renal failure standard diet rats
Fig. 1. Effect of increasing doses of N-terminal parathyroid hormone-
related protein (PTHrP) 1-40 on the secretory response of PTH to an
acute induction of hypocalcemiain normal rats. Hypocalcemia (A ) was
induced by an ethyleneglycol tetraacetic acid (EGTA) infusion. The
rate of reduction of plasma Ca was similar in all groups of rats (B ).
A bolus of PTHrP 1-40 or vehicle was injected at time 0. PTHrP 1-40
enhanced significantly (P  0.01) in a dose-related manner the low
Ca-stimulated PTH secretion. N  6 in each group, mean  SEM.
level of 61  22 pg/mL to a maximum PTH level of
Fig. 2. Representative electropherograms of parathyroid hormone/
196  29 pg/mL in the vehicle-treated group and from parathyroid hormone-related protein (PTH/PTHrP) receptor mRNAs
in three different samples of normal rat kidney cortex and parathyroida basal PTH level of 78  25 pg/mL to a maximum PTH
glands.level of 488  68 pg/mL in the PTHrP-treated group. In
uremic rats, PTH increased from a basal PTH level of
242  45 pg/mL to a maximum PTH level of 382  58 sponse to PTHrP compared to that of hypocalcemia
pg/mL in the vehicle-treated group and from a basal alone was, however, the same in normal and uremic rats.
PTH level of 209  50 pg/mL to a maximum PTH level Thus, in normal rats maximal PTH was increased by
of 826  184 pg/mL in the PTHrP-treated group. The 249% by PTHrP, while in uremic rats PTHrP increased
the PTH response by 216% (NS).proportion of the increment in PTH secretion in re-
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Fig. 3. The relative secretory capacity of the parathyroid glands in
normal rats, uremic rats kept on normal diet [chronic renal failure
(CRF)], and uremic rats kept on high phosphorus diet [CRF high
phosphorus (P)]. The relative secretory capacity is defined as the rela-
tive increase in parathyroid hormone (PTH) secretion from baseline in
response to an acute induction of hypocalcemia, and expressed in per-
cent of basal PTH levels. The relative secretory capacity is significantly
decreased in uremia (P  0.05) and practically 0 in uremic rats kept
on high phosphorus diet. N  6 to 9, mean  SEM.
The PTH secretory response to PTHrP and hypocal-
cemia in uremic rats kept on a high phosphorus diet is Fig. 4. The effect of parathyroid hormone-related protein (PTHrP)
shown in Figure 5. In uremic rats given a high phosphorus 1-40 on the secretory response of parathyroid hormone (PTH) to an
acute induction of hypocalcemia in uremic rats kept on a standard dietdiet, the PTH levels, at the basal condition, were already
(- - -) and in normal rats (______) (A ). Hypocalcemia was induced by anat the upper part of the calcium/PTH curve. Induction ethyleneglycol tetraacetic acid (EGTA) infusion. The rate of reduction
of even severe hypocalcemia was not able to stimulate of plasma Ca was similar in all groups of rats (B). A bolus of PTHrP
1-40 or vehicle was injected at time 0. PTHrP significantly enhancedPTH secretion further. PTHrP administration, however,
the low Ca-stimulated PTH secretion in both group of rats (P enhanced the PTH levels significantly (P  0.001) and 0.01). N  6 in each group, mean  SEM. CRF is chronic renal failure.
the continuous increase strongly suggests that a maxi-
mum was not even obtained in the present experimental
the rate of decrease was similar in the group of ratsdesign.
infused with PTHrP and in the control group of rats.The relative secretory capacity of PTH secretion was
Therefore, differences in the degree of hypocalcemiasignificantly increased by PTHrP administration to ure-
cannot explain the difference obtained in the responsemic rats kept on a high phosphorus diet (P  0.01), as
of PTH secretion to hypocalcemia. We have previouslyshown in Figure 6.
shown in normal rats that the peripheral metabolism of
PTH was not affected by PTHrP. In uremia, however,
DISCUSSION an influence of PTHrP on the peripheral metabolism of
In the present investigation it is shown that N-terminal PTH cannot be completely excluded. In general, elevated
PTHrP administered in vivo in a dose-related manner circulating levels of PTH in uremic HPT might be an
enhanced the secretory response of PTH to hypocal- expression of both a marked increase in glandular secre-
cemia in rats. In uremic rats, the maximal PTH secretory tion and of a reduced elimination of PTH [25], which is
response to low calcium was significantly enhanced com- of importance for the interpretation of the results ob-
pared to that of normal rats, and this response was fur- tained in vivo.
ther increased several fold by the administration of The parathyroid glands are not controlled by a supe-
PTHrP. It has previously been demonstrated that the rior hypothalamic-pituitary axis, as it most often is ob-
maximal PTH secretory response is dependent upon the served in other endocrine glands [26]. Therefore, the
rate of fall of plasma Ca [23, 24]. In the present investi- parathyroid glands are likely to use autocrine/paracrine
gation, the rate of decrease in plasma Ca was well regulatory mechanisms. The PTH/PTHrP receptor was
in the present investigation demonstrated in rat parathy-controlled by the infusion of the calcium chelator and
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Fig. 5. The Ca/parathyroid hormone (PTH) relationship during eth-
Fig. 6. The relative secretory capacity of the parathyroids in uremicyleneglycol tetraacetic acid (EGTA)-induced hypocalcemia in uremic
rats kept on a high phosphorus diet after administration of parathyroidrats kept on a high phosphorus diet and receiving a bolus injection of
hormone-related protein (PTHrP) 1-40. The relative secretory capacityparathyroid hormone-related protein (PTHrP) 1-40 or vehicle. The
is defined as the relative increase in parathyroid hormone (PTH) secre-arrow depicts the direction of change of plasma Ca. In the vehicle-
tion from baseline in response to an acute induction of hypocalcemia,treated rats, induction of severe hypocalcemia did not further enhance
and expressed in percent of basal PTH levels. The relative secretoryPTH levels. Administration of PTHrP 1-40 did, however, enhance the
capacity is significantly increased by PTHrP (P  0.01). N  9 in eachPTH levels significantly (P  0.001). N  9 in each group, mean 
group, mean  SEM. EGTA is ethyleneglycol tetraacetic acid.SEM.
roid glands and has previously been demonstrated in Our observation, that activation of the PTH/PTHrP re-
ceptor increases PTH secretion by several fold, but onlyhuman parathyroid tissue [18]. This supports the possibil-
ity that PTHrP, as a ligand for the receptor, might regu- during hypocalcemia, suggests a possibility for amplifi-
cation of PTH release by PTH itself, when an increasedlate PTH secretion, but also that PTH-producing para-
thyroid cells are target for an autoregulatory action of level is needed. Cultured parathyroid cells in contact
with others parathyroid cells have been shown to secreteN-terminal PTH. On the basis of the present results,
which showed that N-terminal PTHrP very fast, within more PTH than isolated parathyroid cells [28]. This re-
sult has not been explained, but could be mediated by5 minutes, and in a dose-related manner enhanced the
PTH secretory response to hypocalcemia, we would like PTH from one cell stimulating further release from the
neighboring cells. Finally, a transient nature of the initialto propose a model for the existence of a positive auto-
feedback regulatory mechanism of N-terminal PTH on increase of PTH levels in response to a reduction in
plasma Ca has been described in human subjects andits own secretion. PTH is secreted by parathyroid glands,
there are PTH/PTHrP receptors on the parathyroid cells in rats [1, 29]. A rapid and pronounced decrease in
plasma Ca is followed by an initial rapid increase in[18] and PTH is an equipotent ligand to PTHrP for this
receptor [20]. Thus, our hypothesis is that PTH in a plasma PTH level, which soon declines to a new lower
level, despite a continuous fall in plasma Ca. It ishypocalcemic condition enhances its own secretion by a
paracrine/autocrine mechanism. It has, however, to be reasonable to speculate that a positive feedback would
cause augmented secretion during the initial stage ofstated that the in vivo models will not exactly reflect
the events at the paracrine/autocrine level. The possible elevated PTH levels giving rise to a greater bolus of PTH
release. Then, other inhibitory factors must eventuallyexistence of such a positive feedback will allow for expla-
nation of several phenomena in the parathyroid glands. take over to suppress the PTH release. As such, several
inhibitory paracrine/autocrine factors have been pro-The suppression of PTH secretion by Ca is mediated
via activation of the calcium-sensing receptor on the posed (e.g., chromogranin A–related peptides and endo-
thelin-1) [30–32].parathyroid cell surface [27]. How low Ca stimulates
PTH release from the parathyroid cells remains obscure. Autoreceptor effects on hormone or neurotransmitter
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secretion are well known. Most autoreceptors mediate also in the case of uremia is the level of PTH, which has
been considered as the maximal secretory activity of thea negative feedback on the secretion. We are, however,
not alone with the theory of the existence of a positive parathyroid cells, in fact, not the maximum, and that the
maximal PTH secretion can be enhanced even furtherautoregulatory feedback mechanism relating to PTH, as
the beta cell insulin system appears to be a rare example by several fold. As such, the present results oppose the
common assumption, that the maximal PTH secretion isof such a positive feedback of insulin on the secretion of
insulin [33–37]. A possible link between impaired insulin an expression of the parathyroid mass [45]. The secretory
response of the parathyroid glands to hypocalcemia is asecretion and insulin resistance at the level of the pan-
creas has been suggested as a mechanism involved in the tightly regulated phenomenon, which is mediated via a
combined influence of extracellular Ca and a spectrumdevelopment of type 2 diabetes [34, 35].
We speculated that an eventual disturbed response to of paracrine and autocrine factors [45], which might in-
clude peptides targeting the PTH/PTHrP receptor.the PTH/PTHrP receptor ligand might be an additional
factor in the increased PTH secretion in secondary HPT The hypercalcemia of malignancy in human subjects
arises from an inappropriate activation of the renal anddue to uremia. The present results, however, contradict
such a possibility as the increase in PTH secretion in bone PTH/PTHrP receptors by PTHrP, which is gener-
ated by the malignant cells. In this condition the PTHresponse to PTHrP was proportionally the same in ure-
mic rats on a standard diet and normal rats. The pattern secretion from the parathyroid glands is suppressed.
of the continued and progressive increase in the high When plasma PTH levels are elevated, a concomitant
phosphorus uremic rats given PTHrP seems to be differ- primary HPT is considered. In a previous study, we have
ent. The explanation for this continued rise of PTH in shown that PTH levels were suppressed during hypercal-
that group is not clear from the present investigation. cemia despite PTHrP administration [1]. This is in agree-
The relative secretory capacity of the parathyroid ment with the clinical findings with the hypercalcemia
glands is in the present investigation shown to be severely of malignancy.
diminished in uremic animals. The physiologic impor-
tance of this observation is at present not clear. The
CONCLUSIONfluctuation of plasma PTH levels is possibly of impor-
PTHrP enhanced significantly the low Ca-stimu-tance for maintaining the sensitivity of bone cells to PTH
lated PTH secretion in vivo in a dose-related mannerand for maintaining normal bone metabolism [38–40].
in normal rats. The impaired secretory capacity of theAn abnormal fluctuation of plasma PTH levels has been
parathyroid glands in uremic rats was significantly en-described in patients with metabolic bone diseases, as
hanced by PTHrP. The presence of the PTH/PTHrPsuch diminished circadian fluctuations of PTH have been
receptor is demonstrated in rat parathyroid glands inreported in patients with age-related osteoporosis [38]
the present investigation. An autocrine/paracrine role ofand osteoporotic subjects exhibited a disturbed pulse
PTH/PTHrP receptor targeting peptides in the parathy-amplitude and frequency modulation of PTH secretion
roid glands is suggested. Thus, PTH might during hypo-with smaller and less pulses [41]. Altered calcium-modu-
calcemia have a positive auto-feedback regulatory rolelated oscillatory PTH secretion pattern has also been
on its own secretion.shown in patients with secondary HPT with increased
spontaneous PTH burst frequency, but with blunted re-
sponsiveness to changes in Ca[42]. Treatment of os- ACKNOWLEDGMENTS
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